Futuresinfocus

Astellas Pharma Inc.Chief Commercial Officer, Claus Zieler, envisions this future. The shift from chronic treatment to highly personalized, one-off treatments is not far ahead of us. By 2033, this approach will be commonplace rather than an unusual outlier.In the medical industry, we can already witness the initial signs of this emerging future where AI is starting to transform the landscape of pharmaceutical discoveries currently in progress.Traditionally, the medical industry has followed extended timelines for discovery, testing, and market validation. Breakthrough treatment protocols usually emerge sequentially rather than concurrently. However, the integration of AI with these breakthroughs promises to accelerate the pace and broaden the impact, ultimately reshaping the healthcare system as a whole.Developing a new drug typically costs $2 billion and involves a 10-year development cycle with thousands of patients. AI simulations have the potential to significantly reduce costs and time while fostering in